App-Quantinova.ai

Feasibility, safety and efficacy of concomitant ponatinib with apixaban, as prophylaxis for arterial and venous thrombosis in patients with chronic myeloid leukaemia (CML) pre‐ and post‐allogeneic stem cell transplantation.

J. Schofield - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic Myelogenous Leukemia

Ponatinib

Periprocedural anticoagulation in mechanical heart valve patients – a single centre review of practice

R. Mullally - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Plasma proteomic profiling one year postpartum of women with pre‐eclampsia shows dysregulated cardiometabolic profile

F. Abad - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Paediatric thrombosis: A single centre 8‐month experience

A. Abbas - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Warfarin

Acquired Factor VII deficiency — a rare but important consideration

A. Stanley - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Factor VII deficiency

N/A

Anticoagulation associated upper GI bleeding in Maidstone and Tunbridge Wells NHS Trust

K. Majumder - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

rivaroxaban

A Case of Acquired Haemophilia secondary to Atypical Carcinoid Tumour

N. Prasannan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Hemophilia

Cyclophosphamide

Survey of thromboprophylaxis strategies in renal transplant recipients at a single transplant unit

R. Kohli - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

Heparin

Ninewells Hospital paediatric blood transfusion audit

M. Harrison - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Anemia

N/A

Prophylactic FFP transfusion: are we complying with National guidance?

M. Harrison - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Chronic Liver Disease

Warfarin

Blood Product Usage in Major Obstetric Haemorrhage at Epsom and St Helier Hospitals: A Quality Improvement Project

L. Ellis - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Major obstetric haemorrhage

Fibrinogen (IV)

HHV‐6 as a cause of fever and delayed platelet engraftment in patients undergoing autologous stem cell transplant

F. Hickey - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Establishing the rate of acceptance of a nasogastric feeding tube in allogeneic transplant patients within a national centre

A. Dean - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Mucositis

Hydroxyzine

Retrospective analysis of Intensive Care Unit admission and outcome of Haematopoietic Stem Cell Transplant patients at St. George's Hospital

K. Xu - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Graft-versus-host disease

Cyclophosphamide

When is chronic myeloid leukaemia ‘cured’? Relapse post allogeneic bone marrow transplantation after 32 years

M. Bolaji - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic Myelogenous Leukemia

Cyclophosphamide

Pml nuclear body disruption cooperates in APL pathogenesis, impacting DNA damage repair pathways

E Voisset - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cysteine Hydrochloride

Concurrent treatment of aplastic anaemia (AA)/paroxysmal nocturnal haemoglobinuria (PNH) syndrome with immunosuppressive therapy and eculizumab: a UK experience

M Griffin - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclosporine A

Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐naïve patients

JM Timmerman - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Adcetris

Real world experience with brentuximab vedotin in relapsed/refractory CD30 positive lymphoma: outcomes in 33 patients after prolonged follow‐up at a single UK Centre

K Piddock - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adcetris

Anti‐CD27 enhances lymphoma immunotherapy through myeloid cell recruitment

A Turaj - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Varlilumab

Filters

45280 Abstracts